The strengthening of our working capital succeeded beyond our goals – we are now in a good position to continue with our plan.
We are extremely pleased to have Leena on the Board of Nightingale. She strengthens our understanding of the health technology business in the Board.
Nightingale offers a solution for preventive health on the level of the individual, company and society. I am absolutely thrilled to be part of the revolution of preventive health.
Nightingale’s health data platform has a leading-edge in the global megatrend of consumers wanting to manage and improve their health. It’s a privilege to join Nightingale’s exceptional team and work together towards establishing Nightingale’s technology as the new global standard for preventive health
We are thrilled to have Timo join us. His vast experience in building consumer-centric companies in the digital world will play a key role in Nightingale’s next phase of growth, as we aim to build a more sustainable, engaging and people-oriented preventive healthcare system
Providing better health information tools for individuals is the only sustainable and logical way of delivering preventative health. This not only helps individuals lead healthier lives but also contributes to solving the global burden of chronic diseases
We cannot afford to continue shutting down economies going forward. Rather, we need to enable people to return safely to work and Nightingale’s solution is one of the first to allow targeted prevention before contracting the virus. This is a timely preventative screening tool as it enables the detection of the ones needing special precautions to avoid COVID-19 infection, while allowing the majority to return to work and help get the economy back to normal despite the pandemic.
The best way to detect those at high risk is by looking at a molecular signature of multiple biomarkers. It is striking that the risk identification works well even when focusing on a subset of biomarkers in Nightingale’s blood test that can be captured by self-collection through a finger prick blood sample. These novel findings provide a scalable solution for personalised prevention and population level screening, which can later also be used to prioritise vaccines for those who need it the most.
While getting results requires substantial investments and patience, we have been eager from the very beginning to combine Nightingale’s blood biomarker data with one of the world’s largest health databases, the UK Biobank. We have firmly believed that the population-scale data will reveal a variety of novel medical findings, but the promising results on COVID-19 and pneumonia even surprised us.
While vaccines and drugs play an important role with COVID-19, they are too late for many. Therefore, detecting and protecting the risk groups before they get exposed to the virus is one of the keys for effective COVID-19 strategy. Using the Nightingale blood biomarkers to identify vulnerable people could save lives as the tool could be used to isolate high-risk individuals. Once identified, the high-risk individuals are also able to take extra precautionary measures to protect themselves from the virus and eventually be prioritised for novel vaccines produced at limited capacity.
The initial findings by Nightingale’s scientists for COVID-19 and pneumonia must naturally be validated but they show great promise. By joint studies of many European cohorts, we have previously made landmark scientific findings with the Nightingale blood biomarkers as indicators of physiological and mental vulnerability. With the UK Biobank data, we strongly believe that many novel findings are waiting to be discovered. We are very excited to collaborate with Nightingale around the very promising results with COVID-19 and pneumonia.
The initial results with COVID-19 and pneumonia by combining Nightingale technology and the UK Biobank are truly exciting and very timely. However, this is just the tip of the iceberg. We have completed the first batch of 125,000 samples and I’m expecting a wealth of novel findings in the near future while we continue the blood sample analyses up to 500,000 UK Biobank samples. The power of large-scale population data is immense and I’m very proud to see how Nightingale’s technology and our collaboration with the world-leading scientists are paving the way towards better global health solutions.
Nightingale's core strategy lies in the intersection of science and preventative health applications. We believe that brings benefits in the form of new scientific findings but simultaneously also help people have healthier lives.
We are pleased that these well-renowned scientists will help us strengthen the science emerging from our global biobank initiatives. Nightingale remains committed to taking our innovative biomarker offerings beyond applications for population health research with the strongest possible scientific underpinnings.
We are delighted to have Mr. Närhinen as an investor, but more importantly, we are very honoured to have one of the most experienced healthcare professionals in Europe to support us in taking Nightingale’s technology to global healthcare markets.
In order to improve healthcare in large scale, we need practical tools that enable early detection and active prevention of chronic diseases. Nightingale’s blood testing technology has the potential of being the game changer in this regard, enabling truly preventative healthcare for people.
I want to share my connections and experience in growing major healthcare business with Nightingale’s top management and the Board of directors. They have an unprecedented opportunity to shape the future of global healthcare with their technology
Having Mr. Närhinen as a strategic advisor with an independent perspective will significantly help Nightingale to focus on the most promising international market opportunities. With our proven world-leading technology and exceptional team, we are in an excellent position to rapidly grow our business and continue our journey in helping everyone to live and extend healthy life
Abolishing chronic diseases demands democratising preventive health. Nightingale therefore wants to give people the best possible tools to take care of their health. Our mission is to build a health-creation system enabling a preventive health journey for everyone.
We are giving individuals access to health information that was previously available only for scientists. That’s because our aim is to equip people with the best tools that can help them increase their health spans and live healthy lives.
Imagine, if personal success stories in improving health from around the world could benefit thousands of others in similar health situations. We foresee a future where knowledge of health doesn’t remain in silos but is shared to create collective knowledge that benefits the health of individuals, communities and the whole society.
Our global position in scientific validation, technology readiness, regulative approvals and product availability is extremely good and in many areas second to none. Creating biotechnology based health solutions for mass-market is one of the most challenging tasks there is, but the Nightingale Team has made it –– and now we are ready to scale out.
We are pleased to announce this strategic partnership with Nightingale to bring preventative health and wellness solutions together with our partner company Kirin
I believe Nightingale’s blood-test provides very valuable biomarker information about health in chronic diseases. When integrating the biomarkers with multiple health-related data sources and machine learning, we will have crucial knowledge to develop new nutritional products
Our research will give new insights into the metabolic disturbances that precede and predict diabetes in Asian populations. We hope that this will enable us to better understand disease pathways, and to develop new approaches for identification of high-risk South Asian people who may benefit from early intervention.
Traditionally, technological constraints and high costs have impeded researchers from doing such large-scale population analysis. We are happy to provide a technology that can measure over 220 metabolic biomarkers from a single blood sample at very reasonable costs. This supports scientists to make massive breakthroughs in medical science.
We face a huge challenge with the athletes training for international games like the Olympics or other world championships as, very often, they fall ill right before a big competition and a lot of the work goes to waste. However, currently, we don’t have enough knowledge around respiratory infections and immunology in sports medicine to be able to prevent and truly understand such a scenario.
I have had to deal with infections on several occasions earlier in my career. The situation is more stable now, but I really hope that the study results will be able to guide athletes on how to take better care of themselves and improve performance.
Nightingale’s technology is not only versatile but pioneering in preventive care as it offers details about your health that was not revealed to you before. This will give everyone a chance to improve their lifestyle and live healthier lives.
Nightingale has been involved in some of the world’s largest metabolomics projects, including being selected to analyse the entire UK Biobank cohort of 500 000 samples, the national biobank of Finland (THL Biobank) and the Mexico City Prospective Cohort in coordination with Oxford University. We’re now looking to expand the use of our platform with ground-breaking initiatives in the U.S., and further enhance public health research with large studies worldwide
We are pleased that Nightingale selected our clinical laboratory in Pittsburgh to expand its innovative biomarker analysis offering to customers here in the U.S.
The Singapore Multiethnic Cohort creates a unique research setting to study how to improve the prediction of type 2 diabetes, coronary artery calcification, and changes in cardiovascular risk factors in the Singaporean population. Nightingale’s technology creates a novel opportunity to look at a broad profile of metabolic markers, potentially enhancing the understanding of disease development.
It’s an interesting opportunity to examine how these biomarkers are associated with dietary and other lifestyle factors and may mediate associations between lifestyle factors, cardiovascular disease risk factors, and risk of type 2 diabetes. Moreover, potential biomarker associations can be replicated with other studies around the world carried out using Nightingale’s technology, enabling more detailed analysis of the findings in Singapore.
Nightingale’s blood analysis technology is a global platform. This means that samples measured with our technology all over the world can be combined, compared and replicated. We are excited about this initiative with NUS, as it brings large-scale Southeast Asian sample collections to an international platform, benefitting medical researchers in Singapore and South East Asia but also having a global impact.
Nightingale is committed to continuous improvement and nowhere is this more important than in delivering our clinical service to the highest standard.
From the beginning we’ve put quality and the needs of regulatory requirements at the centre of our strategy.
Chronic diseases are a nightmare, not only for those who suffer from them, but also for those trying to cure them. The EIB is committed to supporting companies like Nightingale that can realistically make a big impact and improve the health of EU citizens. The support of the Investment Plan for Europe is particularly valuable here, and the operation is fully aligned with the objective of supporting high-skilled employment opportunities. This will also enhance Europe’s position as a major leader in medical innovation.
Europe invests heavily in education and science as we believe that putting a strategic effort into these areas can reap huge benefits. This commitment has resulted in Europe’s position today as a world leader in cutting edge medical research. We are delighted that the Investment Plan for Europe is fostering the development of Nightingale’s technology which has the potential to add significant value to European healthcare.
Nightingale wants to create a world where healthcare keeps people healthy throughout their lifetimes, not just whenever they get sick. When we founded Nightingale in 2013, we wanted to bring together innovations from biotechnology, medicine and computer sciences to build a different type of healthcare – one where everyone is given a chance to live a healthier life. Today’s announcement provides Nightingale with the funding needed to take our vision for personalized medicine into European healthcare. By supplying physicians with accurate chronic disease risk prediction for their patients, we will empower people to better understand their own health status and take actions to reduce their risk. Not only will this transform how we treat common diseases such as diabetes and heart disease, but it will also significantly reduce the current economic burden on healthcare systems and workforces.
In addition to treating the symptoms and complications of diseases like type 2 diabetes, we should be equipping people with the best possible tools to keep themselves healthier for longer, and making them available at an affordable price. Virta 360 is a health concept for the 21st century. By combining molecular insights related to physical health with advanced digital health applications that measure lifestyle habits, we can better understand a person’s overall health status and allow them to proactively improve their wellbeing.
An individual’s wellbeing is influenced by all aspects of their life, from nutrition to personal relationships. These are reflected by changes in a person’s blood, providing an indication of their future wellbeing. Virta 360, for the very first time, allows people to fully understand how their lifestyle habits are impacting their health and provides them with better tools to keep their wellbeing on track.
As we have seen in numerous studieswith thousands of study volunteers,GlycA has considerable potential as a marker of chronic inflammation that can effectively predict disease onset and prognosis. The findings of this paper add further evidence to support the measurement of GlycA in national biobanks, as well as its utility in future clinical applications
Nightingale’s mission is strongly linked to scientific evidence generation. This means working with world-leading institutions and biosample collections to continuously improve the understanding of health and disease. Our aim is to translate this understanding into improved early prediction of diabetes and cardiovascular diseases, achieving better healthcare for everyone. Our initiative with the UK Biobank demonstrates Nightingale’s unwavering commitment towards supporting innovative medical science carried out by researchers from across the world.
We are delighted to see these novel blood sample analyses being done in UK Biobank. We already have an enormous amount of information about the lifestyles and genetic make-up of the participants in UK Biobank, as well as about their health, and are currently conducting imaging studies of their brains, hearts and bodies. Providing the medical research community with these additional high quality metabolic biomarker data on such a large scale will enhance discovery science and population science, providing opportunities to benefit patient care and public health.
Analysing 500,000 blood samples from a single study with Nightingale’s comprehensive biomarker profiling technology allows us to uncover metabolic signatures that reflect a risk for future disease onset, as well as their underlying risk factors. We anticipate this detailed molecular readout of the health state, combining both lifestyle and genetic makeup, will result in a wealth of scientific applications from the research community. This will be relevant not only to the British population but also yield ground-breaking science and enhanced drug development opportunities with a global public health impact.
We are excited to be able to expand our metabolomics offerings in the fall of 2018. Our urine, cerebrospinal fluid (CSF) and umbilical cord blood services will allow us to provide researchers with a pervasive and more complete picture of human health. The ability to compare changes in the metabolic profiles of the different bio-fluids is especially interesting and will further the molecular understanding of health and disease.
"We believe that our technology will provide better tools for the prevention of chronic diseases in primary care. Solving the prevailing issues in healthcare today requires the development of cutting-edge innovations and the courage to take advantage of the possibilities they bring. We are honored to receive this award and industry support, as we continue to make strides towards bringing our service to healthcare systems globally.”
We’re proud to have received recognition from the Health Awards jury for our impact on the current debate taking place in the Finnish healthcare sector. As innovators in the healthcare space we aim to switch the primary strategy of the current system from disease treatment to disease prevention, replacing routinely used cholesterol tests worldwide.
It’s an honor to receive recognition from EuropaBio’s jury panel of biotech experts and be invited to speak at the EU parliament. We believe our blood analysis technology has the potential to make a considerable contribution to society through improving early disease detection in healthcare, particularly in primary care. By allowing patients to take an active role in their own health maintenance, we can switch the focus in healthcare from treatment to prevention
"Coronaria aims to build a novel healthcare system in Finland that will benefit all of us, with patients receiving better care, personnel achieving more and society saving money. The emphasis in healthcare must be shifted to preventive and personalized care, especially for chronic disease treatments. We see Nightingale's blood analysis as an important tool to achieve this goal. As a result, we wanted to be the first to pilot the service in Finland",